Extended Data Fig. 6: Grouped boxplots of difference in mean log2 marker level of upregulated proteins by clinical outcome using DSP of the TME in pretreatment biopsies and post-treatment prostatectomies following B7-H3 monoclonal antibody treatment.
From: Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
a, protein marker status by PSA response (PSA < 0.1 ng/mL) at 12 months after prostatectomy versus PSA recurrence. Protein expression was assessed in n = 27 tissue samples from n = 32 patients (n = 18 responders and n = 9 non-responders). b, protein marker status by Gleason grade group change from biopsy to prostatectomy. Protein expression was assessed in n = 27 tissue samples from n = 32 patients (n = 14 decline in Gleason and n = 13 no decline in Gleason). Median (IQR) data is presented and whiskers indicate the minimum and maximum values.
